Lyvgen Biopharma Website 礼进生物英文官网

Immune-oncology Agonistic Antibodies
Clinical Development Candidates
LVGN6051
Next generation CD137/4-1BB agonistic monoclonal antibody
LVGN6051 is designed to stimulate the proliferation and cytotoxicity of antitumor immune cells. Optimal efficacy and safety profile are achieved by the crosslinking dependent CD137 agonistic activity through FcγRIIB.

LVGN7409
Next generation CD40 agonistic monoclonal antibody
CD40 activation by LVGN7409 promotes tumor antigen presentation and induction of cancer-fighting T cells, and "warm up" the immune-"cold" tumor microenvironment. Unique structure and functionality of LVGN7409 permits its higher tolerable dosage and broader clinical utility.

LVGN3616
Proprietary PD-1 blocking monoclonal antibody
LVGN3616 blocks PD-1 pathway to unleash the "brake" of the immune responses against cancer.
Lyvgen xLinkAb platform
xLinkAb Avidity Cross-linking Synthetic Immunity
xLinkMAb
Cross-linking monoclonal antibodies
Target activation dependent on FcγRIIB engagement
TROY-Ig
Cross-linking multi-specific antibodies
New generation CD3 T cell engager with co-stimulation
IgG-like design
Inquiries

General ------------------------------ ---Business Development----------------------------Employment--------------------------------------Clinical
info@lyvgen.com -----------------1 bd@lyvgen.com ------------ ----- careers@lyvgen.com ------------------ clinical@lyvgen.com

Phone +86 021-50663350
Contact us on LinkedIn
Copyright © 2022 LYVGEN BIOPHARMA. All Rights Reserved. Lyvgen website is designed to provide general information about the subject matter presented. The information presented does not, and is not intended to, provide medical advice.